Work

First-in-human phase I/II study of a highly selective FGFR2 inhibitor 3HP-2827 in patients with advanced solid tumors harboring FGFR2 alterations.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.3114

Authors: Jiajia Yuan, Jia Fan, Tianshu Liu, Xianglin Yuan, Haitao Zhao, Zhengbo Song, Ning Li, Yanhong Gu, Yanqiao Zhang, Beicheng Sun, Yingying Du, Li Enxiao, Yi He, Lin Shen

Institutions: Peking University Cancer Hospital, Fudan University, Zhongshan Hospital, Tongji Hospital, Peking Union Medical College Hospital, Zhejiang Cancer Hospital, Henan Cancer Hospital, Jiangsu Province Hospital, Third Affiliated Hospital of Harbin Medical University, Anhui Medical University, First Affiliated Hospital of Anhui Medical University, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an Jiaotong University, Hunan Cancer Hospital

Language: English

Topic: Cholangiocarcinoma and Gallbladder Cancer Studies

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162548366

Cites:

Cited by:

Related to: